Synonyms: Acetate, Mitoxantrone; CL 232325; Mitroxone; Spectrum5_001205; Lopac-M-6545; cid_4212; Neuro_000153; SCHEMBL3000; BIDD:PXR0181; Lopac0_000779; BSPBio_000569; BSPBio_003160; KBioGR_001531; Novantron; KBioSS_002135; AN-584/42007670; DivK1c_000516; SPBio_000756; SPBio_002490; BPBio1_000627; GTPL7242; Novantrone(R) (mitoxantrone for injection concentrate); DTXSID4046947; BDBM67690; Novantrone; cid_5458171; CTK8A5416; KBio1_000516; KBio2_002135; KBio2_004703; KBio2_007271; KBio3_002660; NINDS_000516; HMS2090D05; HMS3655E20; NSC 279836; KUC108634N; BCP02861; EBD32557; ZINC3794794; CCG-36371; CM0184; s1889; STK631833; Mitoxantrone hydrochloride (Salt/Mix); AKOS005564036; NSC 287836; API0003408; BCP9000931; CS-2524; DB01204; KSC-19-204; MCULE-5513787065; IDI1_000516; SMP2_000179; NCGC00015693-01; NCGC00015693-03; NSC 299195; NCGC00015693-04; NCGC00015693-05; NCGC00015693-06; NCGC00015693-08; NCGC00162251-01; AK323601; AN-14761; AN-38696; AS-35321; BC651765; NSC 301739; HY-13502; K061; LS-20638; MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE; MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; NCI60_002276; NCI60_002535; SC-22733; SMR001549953; SY226320; NSC 301739D; SBI-0050757.P003; TX-017756; AB00053716; FT-0630752; SW196745-6; MFCD00242942 (95%); VU0244399-2; 71M809; C11195; D08224; NSC-279836; 13181-EP2270008A1; 13181-EP2270505A1; 13181-EP2272827A1; 13181-EP2275420A1; 13181-EP2277876A1; 13181-EP2289892A1; 13181-EP2292617A1; 13181-EP2295055A2; 13181-EP2295412A1; 13181-EP2295413A1; NSC-287836; 13181-EP2295416A2; 13181-EP2295426A1; 13181-EP2295427A1; 13181-EP2298748A2; 13181-EP2298764A1; 13181-EP2298765A1; 13181-EP2301928A1; 13181-EP2305642A2; 13181-EP2305660A1; 13181-EP2311453A1; CL-232325; NSC-299195; 13181-EP2311808A1; 13181-EP2311829A1; 13181-EP2311837A1; 13181-EP2311840A1; 13181-EP2311842A2; 13181-EP2316832A1; 13181-EP2316833A1; 13181-EP2316834A1; AB00053716-18; AB00053716-19; NSC-301739; AB00053716-22; AB00053716_23; AB00053716_24; SR-01000076001-7; BRD-K21680192-001-01-5; BRD-K21680192-001-11-4; BRD-K21680192-300-05-2; BRD-K21680192-300-07-8; BRD-K21680192-300-09-4; BRD-K21680192-300-10-2; NSC-301739D; BRD-K21680192-300-12-8; 1,4-bis[2-(2-hydroxyethylamino)-ethylamino]-5,8-dihydroxyanthraquinone; 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone; 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone; 9, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] amino]-; 1,4-Bis[[2-[(2-hydroxyethyl)amino]ethyl]imino]-1,4-dihydroanthracene-5,8,9,10-tetrol; 1,4-Dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-9,10-anthraquinone;hydrochloride; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-anthracene-9,10-dione; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;hydrochloride; NSC279836; 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-bis(oxidanyl)anthracene-9,10-dione;hydrochloride; 1,4-dihydroxy-5,8-bis[2-[(1,1,2,2-tetradeuterio-2-hydroxyethyl)amino]ethylamino]anthracene-9,10-dione; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI); Mitozantrone|||Novantron|||CL-232325|||1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; Novantron; Mitox; nimitoxantron; Mitoxantrone HCl; Misostol; Mitroxone; NSC287836; Onkotrone; Pralifan; Ralenova; Dhaq diacetate; Mitoxantrone 2HCl; Mitoxantrone hydrochloride; Novantrone (TN); Mitoxantrone Acetate; Acetate, Mitoxantrone; Mitoxantrone diacetate; NSC299195; Mitoxantrone dihydrochloride; Mitozantrone hydrochloride; D0R3JB; Hydrochloride, Mitoxantrone; CID4212; MITOXANTHRONE HYDROCHLORIDE; NSC301739D; NSC 299195; NSC-301739; NSC 301739D; NSC301739; NSC287836; C22H28N4O6.2C2H4O2; C22-H28-N4-O6; NSC 287836; NSC 301739; CL232325; CL 232325; CL-232315; CL-232325; 2590B; NSC301739D; C22-H28-N4-O6.2C2-H4-O2; A10595; D008942; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione diacetate; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone 1,4-diaceate; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-(9CI); 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-9,10-anthracenedione diacetate; 70476-82-3; 70711-41-0; Onkotrone; Anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-, 1,4-diacetate (salt); Pralifan; CL232325; Ralenova; mitoxantrone; 65271-80-9; Mitoxanthrone; Mitozantrone; DHAQ; Dihydroxyanthraquinone; Mitoxantron; Novantrone; Mitoxantrona; DHAQ; Mitoxantronum; Mitoxantronum [INN-Latin]; Mitoxantrona [INN-Spanish]; Mitoxantrone [INN]; NSC 279836; UNII-BZ114NVM5P; DHAD; NSC279836; Mitoxantrone (INN); CCRIS 7604; Hydrochloride, Mitoxantrone; C22H28N4O6; NSC-279836; DHAQ HCl; BRN 2795126; BZ114NVM5P; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; Mitoxantrone; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; MLS002703044; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; CHEBI:50729; KKZJGLLVHKMTCM-UHFFFAOYSA-N; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; NSC299195; NSC301739; NSC-299195; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; Mitoxantrone Acetate; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-; ANTHRAQUINONE, 5,8-BIS((2-((2-HYDROXYETHYL)AMINO)ETHYL)AMINO)-1,4-DIHYDROXY-; MIX; MLS001333711; Misostol (TN); 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione; NCGC00015693-02; Mitoxantrone (free base); SMR000058480; Mitoxantrone [INN:BAN]; Mitoxantrone Hydrochloride; CAS-70476-82-3; DHAQ (*Diacetate salt*); SR-01000076001; 2fum; 1,4-dihydroxy-5,8-bis(2-(2-hydroxyethylamino)ethylamino)anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthracene-9,10-dione; NSC-301739D; Immunex (Salt/Mix); NSC-287836; Spectrum_001655; Mitozantrone; Liposome Encapsulated Mitoxantrone (LEM); AC1L1HNY; CHEMBL58; Prestwick0_000385; Prestwick1_000385; Prestwick2_000385; Prestwick3_000385; Spectrum2_000908; Spectrum3_001590; Spectrum4_000866;